EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy

Akihiro Fujimoto, Yuki Ichinose, Kazuo Matsuura, Emi Mikami, Wakako Inohana, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Asami Nukui, Aya Asano, Hiroko Shimada, Hideki Yokogawa und 5 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.08.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Akihiro Fujimoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: afujimot@saitama-med.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant systemic therapy (NST) is the standard of care for high-risk early triple-negative breast cancer (TNBC). Although pathological complete response (pCR) is strongly associated with improved survival, reliable and accessible predictors of response remain limited. The aim of this study was to evaluate whether peripheral blood immune markers and tumor-infiltrating lymphocytes (TILs) can predict pCR in patients with TNBC treated with neoadjuvant pembrolizumab plus chemotherapy. MATERIALS AND METHODS: In this single-institution retrospective study, 60 patients with stage II-III TNBC received NST according to the KEYNOTE-522 regimen followed by curative surgery. Pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and TIL levels were assessed. Associations with pCR were analyzed using logistic regression models. RESULTS: Thirty-six patients (60.0%) achieved pCR. In the univariate analysis, low NLR, high TILs, and histological type were significantly associated with pCR, whereas PLR was not. Multivariate analysis identified low NLR and histological type as independent predictors of pCR. Patients with both low NLR and high TILs demonstrated the highest pCR rate. CONCLUSION: NLR may be a simple and accessible predictor of pCR in patients with TNBC receiving neoadjuvant pembrolizumab plus chemotherapy. Combining peripheral blood immune markers with intratumoral immune parameters may enhance treatment stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoadjuvant TherapyTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeutrophilsLymphocytesHumansFemalePathologic Complete ResponseRetrospective StudiesMiddle AgedLymphocytes, Tumor-InfiltratingAdultAgedPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

Immune checkpoint inhibitorsNeoadjuvant systemic therapyPeripheral blood immune markersTumor-infiltrating lymphocytes

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: afujimot@saitama-med.ac.jp.
  • Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Breast Oncology, Saitama Medical University Hospital, Iruma-gun, Japan.

Zitieren

APA

Fujimoto, A., Ichinose, Y., Matsuura, K., Mikami, E., Inohana, W., Kurosawa, T., Nakame, A., Sakakibara, A., Nukui, A., Asano, A., Shimada, H., Yokogawa, H., Ohara, M., Ishiguro, H., Hasebe, T., Osaki, A., & Saeki, T. (2026). Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.08.013

Vancouver

Fujimoto A, Ichinose Y, Matsuura K, Mikami E, Inohana W, Kurosawa T, et al. Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.08.013

BibTeX
@article{Fujimoto2026,
  author = {Fujimoto, Akihiro and Ichinose, Yuki and Matsuura, Kazuo and Mikami, Emi and Inohana, Wakako and Kurosawa, Taeko and Nakame, Ayako and Sakakibara, Ayaka and Nukui, Asami and Asano, Aya and Shimada, Hiroko and Yokogawa, Hideki and Ohara, Masahiro and Ishiguro, Hiroshi and Hasebe, Takahiro and Osaki, Akihiko and Saeki, Toshiaki},
  title = {Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.08.013}
}
Kostenlos starten →